Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous fecal microbiota transplantation (Tel Aviv Sourasky Medical Center, 0426b9)
- Development stage
- Unknown
- Lead developer
- Tel Aviv Sourasky Medical Center
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Auto Fecal Microbial Transplant (Auto-FMT) is an investigational autologous microbiome-based intervention designed to restore the gut microbial ecosystem following disruption by antibiotic therapy. Developed by the Tel-Aviv Sourasky Medical Center, the procedure involves collecting and processing a patient's own fecal microbiota prior to treatment and re-administering it after the completion of antibiotics. This approach aims to mitigate the side effects of broad-spectrum antibiotics, such as those used for Helicobacter pylori eradication, by replenishing beneficial bacterial species and preventing long-term dysbiosis. It is currently being evaluated in clinical trials for its safety and efficacy when delivered via oral capsules or enema.
- Other names
- Auto Fecal Microbial Transplantfecal auto-transplantationautologous fecal transplant
Beyond the preview
Go deeper on autologous fecal microbiota transplantation (Tel Aviv Sourasky Medical Center, 0426b9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous fecal microbiota transplantation (Tel Aviv Sourasky Medical Center, 0426b9).